Biomarin Pharmaceutical (BMRN) Stock Highlights

62.56 | +0.95%

2024-11-21 00:38:00

BioMarins focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarins Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.

Statistics

Range Today

61.61 62.7

Volume Today 1.19M

Range 1 Year

61.15 99.56

Volume 1 Year 460.35M

Range 3 Year

61.15 117.77

Volume 3 Year 1.11B

Range 10 Year

61.15 151.75

Volume 10 Year 3.55B

Highlights

Market Capitalization 12.78B (large)

Floating Shares 179.19M

Current Price 62.56

Price To Earnings 40.22

Price To Revenue 4.51

Price To Book 2.36

Earnings Per Share 1.66

Payout Ratio 0%

Performance

Latest +0.95%

1 Month -10.62%

3 Months -33.4%

6 Months -19.3%

1 Year -28.36%

3 Years -31.85%

5 Years -19.39%

10 Years -25.99%

Benchmarks

Market Capitalization

9 / 368

Gross Profits

7 / 278

Total Revenue

7 / 300

Total Rank

17 / 368

Free Cashflow

105 / 352

Performance 5 years

147 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.